Reverse merger · Pending · CLYD

Clywedog Therapeutics, Inc.

Reverse merger with Barinthus Biotherapeutics plc (BRNS)

Clywedog Therapeutics, Inc. agreed to merge into Barinthus Biotherapeutics plc (BRNS), a Nasdaq-listed (ADS) clinical-stage immunotherapy biotech, formerly Vaccitech, in a reverse merger that takes the private company public. The deal was announced on Sep 29, 2025. The combined company is expected to trade as Clywedog Therapeutics Holdings, Inc. (CLYD) on Nasdaq.

Clywedog Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs for metabolic disease, led by next-generation menin inhibitors for type 2 diabetes, obesity and type 1 diabetes, and a TYK2 inhibitor for type 1 diabetes.

Status: Pending
Private company: Clywedog Therapeutics, Inc.
Public company: Barinthus Biotherapeutics plc (BRNS)
Public company business before: Nasdaq-listed (ADS) clinical-stage immunotherapy biotech, formerly Vaccitech
Announced: Sep 29, 2025
Combined company: Clywedog Therapeutics Holdings, Inc. (CLYD)
Exchange: Nasdaq
Sector: Biotech & pharma

Filings

8-K amendment to merger agreement Feb 23, 2026
8-K: scheme of arrangement completed, Barinthus delisted Sep 9, 2026
Proxy statement/prospectus (424B3) Apr 23, 2026
Topco 8-K: second amendment to merger agreement Sep 24, 2026
All filings on EDGAR CIK 2094256

Other pending reverse mergers

Avenzo Therapeutics, Inc.into Rallybio Corporation · Jun 1, 2026
Mentari Therapeutics, Inc.into InMed Pharmaceuticals Inc. · May 19, 2026
Eos SENOLYTIX, Inc.into Pulmatrix, Inc. · Mar 26, 2026
Gravitics, Inc.into Non-Invasive Monitoring Systems, Inc. · Mar 6, 2026
Thramann Holdings, LT350, Influence Healthcare, Voyexinto Auddia Inc. · Feb 17, 2026
Dr Ashleys Bio Labs Limitedinto Impact BioMedical Inc. · Jun 21, 2025

More on this deal for subscribers

Filings

Other pending reverse mergers